/Edwards%20Lifesciences%20Corp%20Irvine%2C%20Ca%20campus-by%20Steve%20Cukrov%20via%20Shutterstock.jpg)
With a market cap of $45.6 billion, Edwards Lifesciences Corporation (EW) offers products and technologies for treating advanced cardiovascular diseases internationally. The company’s product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart.
Companies valued at $10 billion or more are generally described as “large-cap stocks”, and Edwards Lifesciences fits this description perfectly. The company specializes in less invasive treatments for patients with heart valve disorders and continues to pioneer technologies that improve patient outcomes and advance cardiovascular care.